Filamin C in Restrictive Cardiomyopathy
Family members were characterized using a standardized questionnaire, physical examination, 12-lead ECG, and echocardiography. Individuals were considered affected if they exhibited evidence of RCM, atrial fibrillation, or atrioventricular septal defects.
Individual II-5 died during an attempted cardiac transplant and their heart was preserved for pathological analyses. Hematoxylin and eosin, Masson trichrome, and Congo red histological stains of paraffin-embedded samples, as well as transmission electron microscopy of formaldehyde-fixed, resin-embedded tissue sections, were performed according to standard techniques.
DNA Isolation, Whole-Exome Sequencing, and Bioinformatic Analyses
Venous blood samples were collected in acid citrate dextrose vacutainers from all enrolled family members and isolated using the Gentra Puregene Blood Kit (Qiagen, Germany). Whole-exome sequencing was performed on 5 affected family members (II-2, III-2, IV-3, II-5, and II-7). Individual II-2 was sequenced using thirdgeneration Agilent SureSelect Target Enrichment assay followed by pair-end sequenced on the Illumina HiSeq 2000 platform at Perkin Elmer (Waltham, MA). After the enrollment of additional family members, whole-exome sequencing was performed on individuals III-2, IV-3, II-5, and II-7 using the fourth-generation Agilent SureSelect assay (Agilent Technologies, Inc) and pair-end sequencing on the Illumina HiSeq 2500 platform at the Beijing Genomics Institute (Shenzhen, China).
The BWA software package was used to map the sequenced reads to the human genome (NCBI Build 37, hg19). 10 The MarkDuplicates function of the Picard software package was used identify duplicate reads. The GATK software package (Broad Institute, Inc, Cambridge, MA) was used to spot-check alignments and to recalibrate base qualities; this software was also used to call single-nucleotide polymorphisms through its UnifiedGenotyper tool. 11 These variants were then filtered according to the following analyses: transmission of variants with disease in all family members, cardiac gene expression profiles, interspecies conservation, predicted effect on protein function, and potential involvement in cardiac-related functional pathways (Tables I and II in the Data Supplement) . Initially, singlenucleotide polymorphisms with a quality score <20 or a strand bias >60 were excluded. After filtering for common variants with a minor allele frequency >0.1% (dbSNP, 1000 Genomes Project, Exome Variant Server, and ExAC) and exclusion of synonymous variants, only variants with transmission in all 5 sequenced family members were considered as potential candidate genes. PolyPhen-2, 12 SIFT, 13 and MutationTaster 14 were used to predict the effects of mutation on protein function, and Phylop was used to examine vertebrate conservation. 15 The protein expression, expressed in reads per kilobase of transcript per million reads mapped, was collected from the GTEx Portal. 16 Finally, transmission was confirmed by Sanger sequencing of amplicons derived from genomic DNA isolated from the peripheral blood of all family members.
The conservation across species of FLNC (filamin C) flanking the identified p.V2297M mutation ( Figure 1C) 
Site-Directed Mutagenesis
A full-length FLNC clone harboring a C-term myc-DDK tag in vector pCMV6 (RC212462) was purchased from Origene. Site-directed mutagenesis to produce the p.V2297M mutation was accomplished using the Gibson Assembly system from New England Biolabs. The primers used in these reactions are located in Table III in the Data Supplement. Sanger sequencing was used to confirm successful final assembly and to screen for unintended mutations.
Immunohistochemistry
Formalin-fixed explanted heart tissue sections from individual II-5 were de-embedded and rehydrated and then subjected to a 30-minute steam chamber incubation in a solution of 10 mmol/L sodium citrate supplemented with 0.05% Tween20 for antigen retrieval. Samples were first labeled with primary antibodies against FLNC (HPA006135; Sigma-Aldrich), myosin heavy chain 2 (sc-53096; Santa Cruz Biotechnology), or α-actinin (ab9465; Abcam) and then labeled with a fluorescent secondary antibody (anti-rabbit Alexa Fluor 488 [A11008] and anti-mouse Alexa Fluor 546 [A11003]; Life Technologies). Samples were then mounted using VECTASHIELD hard-set mounting medium with 4′,6-diamidino-2-phenylindole (H-1200; Vector Laboratories, CA) and imaged on a Zeiss 510 LSM using a 63X Zeiss Plan-APOCHROMAT 1.4NA oil immersion lens.
C2C12 cells were cultured in a 37°C incubator with 5% CO 2 on sterilized glass coverslips coated with poly-l-lysine (P4707; SigmaAldrich) according to conditions described by ATCC. At 75% confluency, cells were transfected with the wild-type FLNC or p.V2297M FLNC vectors using the Lipofectamine LTX kit (Life Technologies, CA) according to the manufacturer's instructions. At 24 hours, posttransfection cells were fixed using 3.5% paraformaldehyde and stained first with an anti-DDK antibody (TA50011; Origene, MD) and then a fluorescent secondary antibody (A11029; Life Technologies). Cells were counterstained for F-actin using 0.02-uM rhodamine-labeled phalloidin (Sigma-Aldrich) and then mounted and imaged as described above.
Contractile Activity Measurements in Stem CellDerived Cardiomyocytes
Human embryonic stem cells (hESCs; WA07 [H7]; WiCell) were maintained and differentiated into a cardiomyocyte lineage by standard protocols known to produce ventricular cardiomyocytes with an immature phenotype. 17, 18 To introduce a single base pair mutation at Chr7: 128494628 (G>A) in hESCs, we designed a single guide RNA (sgRNA) targeting the vicinity of Chr7: 128494628 using the online CRISPR Design tool (http://crispr.mit.edu/) and cloned the sgRNA sequence into plasmid PX458 (Addgene 48138), 19 which carries the nuclease spCas9 fused with an EGFP reporter. A singlestranded oligodeoxynucleotide (ssODN) was synthesized and used as a repair template for homology-directed repair. To initiate genome editing, ≈8×10 6 hESCs were electroporated with the PX458-sgRNA construct (13 µg) and the ssODN (0.5 nmol). Forty-eight hours after electroporation, hESCs positive for EGFP signal were sorted with a BD FACSAria II cell sorter and allowed for expansion into single cell-derived colonies. polymerase chain reaction amplification of the region surrounding Chr7: 128494628 followed by Sanger sequencing was performed to identify colonies with the expected mutation (G>A). Off-target regions were identified using the CRISPR Design tool and are listed in Table IV in the Data Supplement. The highest scoring coding off target was present in FLNA on the X chromosome, which was Sanger sequenced in all clones with no observed mutation ( Figure IA in the Data Supplement). The sequences of the sgRNA and ssODN are as follows:
sgRNA, TACCGTGGCCAGCACGTGCC ssODN, CGCCTACAGCGTGCGCTTTGTGCCCCAGGAAA TGGGGCCCCATACGGTCGCTGTCAAGTACCGTGGCC AGCACATGCCCGGCAGCCCCTTTCAGTTCACTGTGGGG CCGCTGGGTGAAGGTGGTGCCCACAAGGTGCGGGCC GGAGGCACAGGGCT All phenotypic measurements were performed at 12 days postdifferentiation in 3 independent clones. Contractile measurements were conducted as described previously. 20 Briefly, differentiated myocytes were plated at single cell density on a flexible substrate. Cells were field paced at 1 hz using a C-Pace EP stimulator (Ion Optix, Inc). Images were acquired at ≈90 fps on a Nikon A1R confocal microscope under DIC conditions. Pairwise similarity comparison was performed to identify frames in which maximal perturbation (contraction) was observed. Identified frames were used to measure the long axis of the myocyte during maximal contraction and relaxation. Filamin C in Restrictive Cardiomyopathy
Gene Expression and Protein Analysis
Quantitative real-time polymerase chain reaction was performed using a BioRad CFX384 using the TaqMan Gene Expression Master Mix (ThermoFisher). Taqman probes were purchased from ThermoFisher for FLNC (cat No. 4331182) and housekeeping genes GAPDH (cat No. 4331182) and TBP (cat No. 4331182). Relative expression was calculated using the ΔΔCt method.
Subcellular differential detergent fractionation was performed using protocols from Cold Spring Harbor 21 and then quantified using the Pierce BCA Protein Assay Kit (ThermoFisher). Total protein was harvested using Laemmli buffer and then sonicated using a Bioruptor Plus (Diagenode). SDS-PAGE was performed using BioRad TGX gels and transferred to nitrocellulose membrane using a Trans-Blot Turbo Transfer System (BioRad). Equivalent loading was analyzed by staining with PonceauS (Sigma-Aldrich) before probing with anti-FLNC (Sigma-Aldrich 1:2500) and anti-rabbit-HRP (1:10 000) antibodies. Measurement of chemiluminescence was performed using the Clarity ECL Western Blotting Substrate (BioRad) and imaged on an Amersham Imager 600 (GE Healthcare).
Statistical Analyses
Statistical analyses were conducted using Graphpad Prism 7 (GraphPad Software, Inc). All datasets were tested for normality using D'Agostio-Pearson normality tests. Those with normal distributions were subjected to Student t test, whereas those with non-normal distributions were subjected to nonparametric analyses using Mann-Whitney U tests. P values of <0.05 were considered significant.
Results

Clinical Identification of Familial RCM
The proband in the family (II-5) presented with a severe clinical course of progressive heart failure that culminated in a cardiac transplant ( Figures 1A and 2 ). The explanted heart showed a moderate interstitial fibrosis and myocyte hypertrophy. Pathological assessment also showed a mild amyloid deposition in only the atria ( Figure 2C through 2G), findings consistent with previous studies on exclusively atrial amyloid deposition in patients with persistent atrial fibrillation. 22 Because there was no evidence for storage disease or deposition disorder, the pathological findings were consistent with a primary RCM. 
in Restrictive Cardiomyopathy
The patient's sister (II-2) presented aged 51 years with a pulmonary embolism and atrial fibrillation. Since then, she has had recurrent and highly symptomatic atrial fibrillation, despite treatment with multiple antiarrhythmic medications, including flecainide, propafenone, dofetilide, and sotalol. She has also had >30 cardioversions, 3 pulmonary vein ablation procedures, and ultimately implantation of a permanent pacemaker. During the ensuing years, she has also developed progressive symptoms of congestive heart failure. So coronary disease was excluded by coronary angiography. Serial echocardiography revealed no cardiac hypertrophy or left ventricular dilatation but progressive atrial dilation and a restrictive filling pattern using tissue Doppler imaging. At age 58, the patient experienced 2 embolic strokes within 3 days prompting surgical amputation of the left atrial appendage. Pathological analysis revealed moderate-tofocally severe interstitial/replacement fibrosis and myocyte hypertrophy without evidence of storage disease or significant deposition disorder. In aggregate, her presentation was consistent with a diagnosis of RCM.
The daughter of patient II-2 was diagnosed with congestive heart failure and atrial fibrillation (III-2). Recently, an echocardiography of this patient's 14-year-old daughter (IV-3) revealed focal hypertrophy of the papillary muscles and a highly trabeculated ventricle. The patient's father (I-1) and the oldest brother (II-1) were also reported to have had heart failure and a cardiomyopathy. They died at ages 42 and 25 of a stroke and sudden cardiac death, respectively; however, other electrocardiographic and echocardiographic data are unavailable on these 2 family members. Finally, another brother (II-7) was also diagnosed with RCM and atrial fibrillation. For purposes of genetic variant segregation with disease, we used a tiered approach, where first only individuals with diagnosed RCM were considered affected, followed by a secondary hypothesis that the causative variant underlies a cardiac spectrum disorder, which includes RCM. For this second hypothesis, all family members with documented cardiac abnormalities (II-2, II-5, II-7, III-2, and IV-3) were considered affected for purposes of genetic analyses. Patient II-6 was 54 years of age, had no history of cardiac disease-a normal cardiac evaluation-and was, therefore, considered unaffected. None of the affected family members exhibited an overt skeletal muscle myopathy. All other family members were considered to be of unknown status. Clinical characteristics for all individuals are listed in Table.
Identification of an FLNC Mutation as a Causative Variant for Familial RCM
To identify a mutation associated with RCM in this family, genomic DNA was isolated from peripheral blood samples of in a and b) , there was no evidence of a storage disorder or appreciable alteration in sarcomeric architecture. Filamin C in Restrictive Cardiomyopathy 5 family members with RCM or other cardiovascular defects and subjected to whole-exome sequencing. We included the latter to address the hypothesis that the causative mutation might underlie a cardiac spectrum disorder. Exomes were sequenced in excess of 100× coverage, except individual II-2, who had average coverage of 48× because of the use of older enrichment and sequencing technologies. For individual II-2, 70.09% of the targeted regions reached 20× coveragea number that was improved to an average of 98.17% in the remaining samples (Table V in the Data Supplement). An average of 20 566 variants were identified in each individual, of which ≈9855 were missense, nonsense, stopgain, or splice site variants (Table VI in the Data Supplement). Of these variants, 34 were shared between the 3 individuals diagnosed with RCM, whereas only 11 were shared among the 5 sequenced family members. Within the 3 RCM-affected individuals (II-2, II-5, and II-7), no variation in known cardiomyopathy genes, excluding FLNC p.V2297M, was uncovered (Table II in the  Data Supplement) .
Sanger sequencing was then performed for the 5 novel variants in all individuals to identify which transmitted with cardiac abnormalities. Of the 3 which transmit with cardiovascular abnormalities, only variants in Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 and FLNC were predicted to be damaging by Polyphen-2. After examination of cardiac expression and vertebrate conservation, we identified a single candidate variant for further analysis in FLNC (c.6889 G>A; Figure 1B ). FLNC p.V2297M is highly conserved with a PhyloP conservation score of 5.775 ( Figure 1C ) and cardiac expression of 264.1 reads per kilobase of transcript per million reads mapped in the left ventricle, both the highest values of all candidate variants. It was predicted to be probably damaging according to PolyPhen-2, and it was the only variant shared among affected family members that was not present in the ExAC or EVS databases. We next wished to address the possibility that independent variants or modifiers might underlie the congenital manifestations in this family. However, no pathogenic variants in genes known to underlie congenital cardiac disorders were uncovered in individual II-4.
Formalin-fixed, paraffin-embedded ventricular samples from individual II-5 and a RCM-free control were sectioned and labeled for FLNC and the sarcomeric marker α-sarcomeric actin ( Figure 3A ). In the control samples, FLNC displayed a typical subcellular distribution, namely a high level of association with the intercalated disks and with the z-disk region within individual sarcomeres. In contrast, although FLNC continues to be localized to intercalated disk in the samples from individual II-5, there is a markedly diminished association of FLNC with the sarcomeric architecture ( Figure 3A and 3B). To investigate this finding in vitro, a full-length clone of p.V2297M was generated by site-directed mutagenesis of the wild-type FLNC clone RC212462. To analyze localization patterns, we transfected C2C12 myoblasts with overexpression constructs, and at 24 hours post-transfection, we performed fluorescence immunolabeling by detecting the FLAG epitope and F-actin ( Figure II in the Data Supplement). Although undifferentiated C2C12 myoblasts do not form sarcomeres, both wild-type and mutant FLNC localized to the stress fiber ECG and echocardiography parameters were shown from the day of study enrollment. AF indicates atrial fibrillation; ASD, atrial septal defect; CHF, congestive heart failure; FLNC, filamin C; ICD, implanted cardioverter-defibrillator; ID, Identifier; LA, left atrial; LVEF, left ventricular ejection fraction; LVID, left ventricular inner diameter; NA, not available; RCM, restrictive cardiomyopathy; SCD, sudden cardiac death; VSD, ventricular septal defect; and VT, ventricular tachycardia. Filamin C in Restrictive Cardiomyopathy architecture equivalently-the major thin filament cytoskeletal component in nonmyocytes. Given this colocalization, it seems that p.V2297M retains its actin-binding ability conferred by the N-terminal actin-binding domain, suggesting an alternative mechanism for the perturbed localization in the sarcomeres of mature myocardium.
We then used CRISPR-Cas9 combined with homologydriven repair to generate biallelic insertions of p.V2297M in hESCs ( Figure IA in the Data Supplement). We differentiated these cells toward a ventricular cardiomyocyte lineage (MYL3 expression, ≈2070 reads per kilobase of transcript per million reads mapped) and assayed the contractile function of field-paced myocytes plated on a pliable substrate. FLNC-p.V2297M myocytes exhibited significantly reduced contractility as measured by fractional shortening (P=0.004) suggesting an impairment of the contractile apparatus because Figure 3C ). Expression of FLNC was equivalent in both wild-type and p.V2297M cardiomyocytes, with no differences in protein expression level or subcellular fraction ( Figure IIB and IIC in the Data Supplement).
Discussion
In the present study, we have identified a novel mutation in FLNC, p.V2297M, as a potential cause of RCM in a family. This variant is absent from control datasets and cosegregates with disease in a family with strong evidence for a single genetic pathogenesis. Data from a stem cell-derived cardiomyocyte model and immunohistochemical studies in patient samples provide supportive data on the damaging effect of p.V2297M on cardiomyocyte function. Because mutations in FLNC are known to cause cardiomyopathies, and computational evidence supports a deleterious effect, p.V2297M should be classified as a pathogenic variant according to the guidelines of the American College of Medical Genetics and Genomics.
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FLNC in the Context of Other Known Causes of RCM
We have identified a novel cause of RCM because of a mutation in FLNC. Previous identification of RCM-causing mutations have centered on those in the contractile apparatus of the cardiac muscle. These include the myosin heavy chain 7 motor subunit, the contractile anchor cardiac alpha actin, the regulatory subunits troponin I and troponin T, and the scaffolding protein titin.
FLNC encodes Filamin C-1 of the 3 filamin family members found in humans. Although similar to previously identified RCM candidate proteins as a component of the sarcomeric architecture, the function of FLNC is distinct because it acts as a scaffolding and signaling protein instead of directly governing contractile force of the myocyte. All 3 family members of filamin have a highly conserved N-terminal actin-binding domain followed by a series of Ig repeats and C-terminal domains that enable association with integrins and isoformspecific membrane receptors. Expression of the 291kD FLNC protein, in contrast to the ubiquitous expression of FLNB and endothelial enrichment of FLNA, is most prevalent in the striated muscle tissues. In that context, FLNC dimers play a critical role for the linkage of the sarcomeric architecture to the mechanosensory system mediated by integrin-based cellcell or cell-extracellular matrix attachments. 24 In addition to this role, FLNC also localizes to the intercalated disk-the structure found at the border of adjacent myocytes-where it is thought to aid in cell migration and cytoskeletal remodeling. To perform these tasks, FLNC has been demonstrated to bind with a multitude of other sarcomeric and intercalated disk components. V2297 is located in domain 20, part of the carboxy-terminal structure of FLNC, which has been defined as the interaction site for Xin, 25 KY, 26 myotilin, 27 and multiple cadherins. 28, 29 Although the disruptions in the amino-terminal actin-binding domains that lead to the skeletal muscle-centric myofibrillar and distal myopathy are mechanistically understood, the list of interactors in the carboxy-terminal region is likely incomplete. Although identification of the interactome is technically challenging given the density of protein complexes in the sarcomere and the detergent-insoluble nature of many protein components, full identification of FLNC protein-protein interactions, and how known variation affects these interactions, should be the focus of future study. Until then, the biological role for the carboxy-terminal interactions, as well as the functional consequences of their disruption, remains largely unclear.
Role of FLNC in the Heart
Mutations in FLNC were first reported as a cause for myofibrillar familial myopathies 30, 31 and distal myopathies, 32, 33 which are both defects in the structure or function of skeletal muscle tissue. None of these reports indicated any observed cardiac phenotype. More recently, the impact of FLNC variation on the heart has been recognized, including reports on dilated cardiomyopathy, [34] [35] [36] hypertrophic cardiomyopathy, 37, 38 atrial fibrillation, 37, 38 and RCM. 9 The phenotypic spectrum associated with FLNC variation is intriguing, suggesting that variants act through divergent and tissue-specific manner or that variants are modified by other genetic factors present in the given family. Although sequencing results suggested some possible genetic modifiers in the present study, including a variant in TRPV4 39 -a gene which increases in expression with atrial fibrillation, a concrete link between modifiers and phenotype would require a larger sample size or greatly expanded functional modeling. In the present study, we support the role for FLNC variation in RCM, whereas adding evidence that FLNC variation should be considered in manifestations of congenital heart defects. Although most reported variants in FLNC, as well as those reported for FLNA and FLNB, are in distinct domains of the peptide than p.V2297M, many previously reported mutations result in a mislocalization or aggregation of the filamin protein. 38, 40 A comprehensive listing of known FLNC variation in skeletal and cardiac myopathies is displayed in Figure 1D and listed in Table VII in the Data Supplement. Animal models of filamin deficiency also exhibit both skeletal and cardiac phenotypes. [41] [42] [43] To address this possibility in the present report, we examined the subcellular distribution of FLNC in ventricular tissue obtained from the failing heart of individual II-5 after transplant. As evidenced in patient samples harboring the p.V2297M FLNC mutation, the FLNC protein displayed diminished sarcomeric localization when compared with controls. This mislocalization does not seem to be because of aggregation of FLNC, as has been reported for hypertrophic cardiomyopathy, or altered actin-binding capability because localization to F-actin-rich stress fibers was observed in our exogenous overexpression system. Instead, it is likely that altered interactions between mutant FLNC with additional sarcomeric components may underlie the onset of RCM. Uncovering these altered interactions may be critical to understanding the altered contractile states found both clinically and in the stem cell-derived cardiomyocytes. Alternatively, the recognition and rapid degradation of p.V2297M FLNC could lead to a haploinsufficiency-mediated phenotype similar to those observed in DCM-mediating truncation mutations. Ideally, primary tissue samples would provide conclusive information on transcript and protein levels, but tissue samples appropriate for these measurements are not available. Examination of expression in stem cell-derived cardiomyocyte systems Filamin C in Restrictive Cardiomyopathy revealed equivalent total protein levels, suggesting that lossof-function and not haploinsufficiency at the production level may underlie the pathogenic nature of this variant. There is a definitive reduction in fractional shortening in the stem cell-derived cardiomyocyte model, which can be the result of reduced contractile activity or impaired sarcomeric relaxation. Given the inhibited diastolic filling characteristic of RCM, the second of these is the presumed mechanism in the present study. In sum, given the altered localization of FLNC in patient samples and perturbed contractile function of p.V2297M cardiomyocytes, we would classify this as a loss-of-function variant of unclear molecular mechanism. The further definition of the mechanism underlying the p.V2297M-mediated myopathy will likely prove critical to translating these findings into future clinical interventions for RCM or other FLNC-related myopathies.
Clinical Use of FLNC Mutations in RCM
The diagnosis of primary RCM is still a challenge because there is an overlap of clinical and pathological findings between other cardiac diseases that makes it difficult to specifically differentiate RCM from other cardiomyopathies, pericarditis, or storage diseases. 1 Given that there are a series of known causes for RCM, (5-26) the latest Heart Rhythm Society/European Heart Rhythm Association consensus statement from 2011 recommends consideration of genetic testing for patients in whom a cardiologist has established a clinical index of suspicion for RCM based on examination of the patient's clinical history, family history, and electrographic/ echocardiographic phenotype (class IIb). 44 We think that our findings provide an additional gene for inclusion on future RCM genetic testing panels.
Conclusion
We have identified a mutation in a striated muscle-specific actin-binding protein, FLNC, as the cause of pleiotropic syndrome of familial RCM, atrial fibrillation, and congenital heart defects. Our findings further expand on the filaminopathies and expand on the role for FLNC in cardiac development and function. 
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